MSH2

MSH2
Name	MSH2
Uniprot	P43246
Organism	Homo sapiens

MSH2 is a human DNA repair protein encoded by the MSH2 gene on chromosome 2. It functions as a central component of the DNA mismatch repair machinery and forms heterodimers that recognize and initiate correction of replication errors. Defects in this protein are associated with hereditary cancer syndromes and altered responses to chemotherapeutics.

Function

MSH2 operates as a core mismatch recognition subunit that partners with other proteins to detect base–base mismatches and insertion–deletion loops arising during replication and recombination. In human cells it forms heterodimers with MutS homologs to direct downstream processes including excision and resynthesis, coordinating with factors involved in recombination and cell cycle control. The gene product contributes to genomic stability in tissues susceptible to neoplastic transformation and interacts functionally with tumor suppressors and DNA damage response elements.

Structure and Domains

The protein is a member of the MutS family and contains conserved domains responsible for ATP binding, mismatch recognition, and dimerization. Structural studies have resolved ATPase and connector regions that mediate conformational shifts upon ADP/ATP exchange. Crystallographic and cryo-EM analyses of homologous complexes reveal how domain motions enable sliding clamp formation and recruitment of downstream effectors in species ranging from bacteria to eukaryotes.

Role in DNA Mismatch Repair

As part of the canonical mismatch repair pathway, MSH2-containing complexes scan newly replicated duplex DNA and bind to mispaired bases or loops, initiating repair by recruiting exonucleases and DNA polymerases. After damage recognition, ATP-dependent conformational changes promote communication with repair factors that excise the erroneous strand segment and coordinate gap-filling synthesis by replicative polymerases. This pathway interfaces with recombination surveillance and telomere maintenance systems, influencing mutation rates and microsatellite stability in somatic and germline contexts.

Clinical Significance and Mutations

Germline pathogenic variants in the gene encoding this protein underlie autosomal-dominant hereditary cancer predisposition syndromes characterized by early-onset colorectal and endometrial neoplasia. Somatic loss or epigenetic silencing contributes to high microsatellite instability phenotypes observed in subsets of colorectal, gastric, and endometrial carcinomas, with implications for prognosis and therapeutic choices. Specific missense, nonsense, and frameshift alterations disrupt heterodimerization or ATPase activity and are cataloged in clinical variant databases guiding testing strategies in familial cancer clinics and oncology centers.

Interactions and Pathways

This protein forms stable heterodimers with other MutS homologs to execute mismatch recognition and collaborates with exonuclease 1, proliferating cell nuclear antigen, replication factor C, and DNA polymerases during excision and resynthesis steps. It also communicates with checkpoint kinases and ubiquitin–proteasome pathway components to integrate repair with cell cycle arrest and protein turnover. Pathway-level analyses position it within networks governing genomic maintenance, apoptosis regulation, and cellular responses to chemotherapeutic agents that induce mismatches or replication stress.

Model Organisms and Experimental Studies

Functional roles have been elucidated using knockout and knock-in models in mouse and yeast systems, where loss recapitulates increased mutation rates and cancer susceptibility. Cell-based assays employing human cancer cell lines and CRISPR-mediated gene editing dissect domain-specific functions and drug responses, while biochemical reconstitution with purified proteins has defined mismatch recognition, ATP hydrolysis, and sliding clamp behaviors. These experimental platforms inform translational research conducted in clinical laboratories, cancer centers, and collaborative consortia focused on hereditary cancer syndromes.

Category:DNA repair proteins